Interview: Denis Delval – Senior Vice President, Europe West and South,…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. For over sixty years, it has researched, manufactured and distributed drugs of primary importance for human health, allowing people to benefit from new discoveries in medicine, biology and genomics. Today the Group operates in 12 different countries and employs approximately 1,370 employees, 670 of which in Italy.
Alfa Wassermann´s strategy is to focus on the gastro-intestinal area. Already present in IBS, constipation and diarrhoea, with the launch of Rifaximin-alpha 500 they will be active in a further major gastro-intestinal related area, namely hepatic encephalopathy. In France market authorization was received for Rifaximin-alpha 500mg in January 2015. Alfa Wassermann and its partner Norgine will jointly promote and manage the clinical development of Rifaximine alpha 550 mg in France.
Contact
ALFA WASSERMANN PHARMA SAS
67, rue Anatole France
92300 Levallois Perret – France
Ph. +33 1 41 27 25 10 – Fax +33 1 47 58 77 04
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
The president and CEO of AREVA Med, the medical subsidiary of AREVA Group, the biggest nuclear company in the world, discusses the circumstances that inspired AREVA’s foray into nuclear medicine,…
The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all…
The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported,…
Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French…
The Director of the Social Security talks about the need to strengthen the sustainability of the French social security system, how France is attached to its unique system combining a…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
See our Cookie Privacy Policy Here
